Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2016

View Archived Issues

Apixaban equivalent to warfarin in AF patients with cancer

Seattle Genetics initiates phase I study of SGN-CD123A for relapsed/refractory AML

Galenica completes acquisition of Relypsa

BioPontis Alliance for Rare Diseases and VIB enter a strategic partnership

Merck & Co. discontinues development of odanacatib for osteoporosis

Novartis describes discovery of novel PI3Kdelta inhibitor CDZ-173

Allergan studies oral ubrogepant for acute treatment of migraine in phase III

Opsona Therapeutics' OPN-305 granted FDA orphan drug status

GSK initiates phase IIa trial of shigella vaccine in Kenya

ASLAN Pharmaceuticals licenses RON antibody from A*STAR

Amgen obtains global rights to BI-836908 from Boehringer Ingelheim

CADPA biomarker algorithm identifies asymptomatic patients at risk for cardiac events

NIH funds six projects seeking to identify biological factors that influence neural regeneration

Central administration of donepezil improves long-term heart failure prognosis in vivo

Dynavax provides update on recent dialogue with FDA regarding Heplisav-B BLA

Glucox Biotech describes novel NADPH oxidase 4 inhibitors

Bayer Pharma patents Wnt signaling pathway inhibitors

FDA extends IDegLira NDA review

GenSight Biologics' GS-030 receives orphan drug designation and ATMP classification in Europe

Suzhou Zelgen Biosciences presents new farnesoid X receptor agonists

Shanghai De Novo Pharmatech identifies novel IDO1/TDO2 inhibitors

Guangzhou Institutes of Biomedicine and Health divulges UCP 1 activators

New phase II trial assesses CD24Fc for prevention of GvHD

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical generate anti-HER2 antibody-drug conjugate

Genentech reports positive results from phase III OAK study of atezolizumab

New class of FBPase 1 inhibitors identified at Chinese Academy of Medical Sciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...